🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the fight against superbug strains of the bacteria, according to health experts.

An International Public Health Issue

Gonorrhoea infections are increasing around the world, with figures suggesting over 82 million infections annually. Particularly high rates are observed in the African continent and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Researchers anticipate that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in close succession. This treatment, which is employed against UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This milestone signifies a huge turning point in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Testing Results and Global Access

According to findings published in a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which uses two antibiotics. The trial enrolled over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the authority to register and commercialise the drug in numerous regions with limited resources.

Doctors treating patients have shared positive views. Having a single-dose, oral treatment such as this is described as a "game-changer" for managing the epidemic. This is deemed vital to reduce the burden of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.